Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm Basolateral cell membrane Peripheral membrane protein Golgi apparatus membrane Peripheral membrane protein |
Domain |
PF00780 CNH domain PF00069 Protein kinase domain |
Function |
Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion. |
Biological Process |
GO:0000185 activation of MAPKKK activity GO:0000187 activation of MAPK activity GO:0006903 vesicle targeting GO:0007254 JNK cascade GO:0007257 activation of JUN kinase activity GO:0031098 stress-activated protein kinase signaling cascade GO:0032147 activation of protein kinase activity GO:0032872 regulation of stress-activated MAPK cascade GO:0032874 positive regulation of stress-activated MAPK cascade GO:0033674 positive regulation of kinase activity GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0043506 regulation of JUN kinase activity GO:0043507 positive regulation of JUN kinase activity GO:0045860 positive regulation of protein kinase activity GO:0046328 regulation of JNK cascade GO:0046330 positive regulation of JNK cascade GO:0051403 stress-activated MAPK cascade GO:0051640 organelle localization GO:0051648 vesicle localization GO:0051650 establishment of vesicle localization GO:0051656 establishment of organelle localization GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0070304 positive regulation of stress-activated protein kinase signaling cascade GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity |
Molecular Function |
GO:0004674 protein serine/threonine kinase activity GO:0004702 receptor signaling protein serine/threonine kinase activity GO:0005057 receptor signaling protein activity GO:0008349 MAP kinase kinase kinase kinase activity GO:0031435 mitogen-activated protein kinase kinase kinase binding |
Cellular Component |
GO:0016323 basolateral plasma membrane |
KEGG |
hsa04010 MAPK signaling pathway |
Reactome | - |
Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MAP4K2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MAP4K2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MAP4K2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MAP4K2 in various data sets.
|
Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAP4K2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAP4K2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAP4K2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAP4K2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MAP4K2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MAP4K2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MAP4K2 |
Name | mitogen-activated protein kinase kinase kinase kinase 2 |
Aliases | BL44; RAB8IP; B lymphocyte serine/threonine protein kinase; MAPK/ERK kinase kinase kinase 2; MEK kinase kina ...... |
Chromosomal Location | 11q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MAP4K2 collected from DrugBank database. |
There is no record. |